Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393756 | PMC |
| http://dx.doi.org/10.3389/fnbeh.2022.998307 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation.
J Headache Pain
January 2025
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, USA.
Background: Migraine progression, particularly from episodic to chronic migraine (CM), increases disease burden and healthcare costs. Understanding the new concept of "Medication Underuse Headache" should encourage the health care provider to consider early intervention with calcitonin gene-related peptide (CGRP) monoclonal antibodies. Galcanezumab given early in the course of the disease, may prevent migraine chronification and have a robust response, moreso than when initiated in later stages of migraine.
View Article and Find Full Text PDFAcute exacerbation of COPD: Physiotherapy practice and factors that influence management.
S Afr J Physiother
December 2024
Department of Physiotherapy, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a leading cause of morbidity and mortality in South Africa. Physiotherapy practice and factors that influence management of patients with AECOPD are unknown.
Objectives: To explore physiotherapy practice in the management of patients with AECOPD in South African private healthcare settings and to identify and describe factors that influence physiotherapy patient management.
Amyloid-related changes in fluency in patients with subjective cognitive decline.
Alzheimers Dement (Amst)
January 2025
Alzheimer Center Amsterdam, Neurology Amsterdam University Medical Center Amsterdam the Netherlands.
Introduction: We examined semantic and phonemic fluency in individuals with subjective cognitive decline (SCD) in relation to amyloid status and clinical progression.
Methods: A total of 490 individuals with SCD (62 ± 8 years, 42% female, 28% amyloid-positive, 17% clinical progression) completed annual fluency assessments (mean ± SD follow-up 4.3 ± 2.
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib.
Oncol Ther
January 2025
Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Introduction: Myelofibrosis (MF) is often characterized by a multifactorial anemia determined, in part, by bone marrow (BM) fibrosis, extramedullary erythropoiesis and splenomegaly. Ruxolitinib (RUX) is the first-in-class janus kinase 2 (JAK2) inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. The red cell distribution width (RDW) is the measure of erythrocyte volume variability (anisocytosis).
View Article and Find Full Text PDFRevealing the Importance of a Multidisciplinary Approach to Reducing the Global Burden of SLD Through the COVID-19 Pandemic: Editorial on "Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023".
Clin Mol Hepatol
January 2025
Department of internal medicine and liver research institute, Seoul national university hospital, Seoul national university college of medicine, Seoul, Korea.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!